Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Next Previous
Trial Profile

NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs ALT 803 (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Brachyury peptide vaccine (Primary) ; CST 101 (Primary) ; ETBX 011 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; Omega-3-acid ethyl esters (Primary) ; Capecitabine; Cisplatin; Cyclophosphamide; Fluorouracil; Folinic acid; Paclitaxel
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NantCell

    • Most Recent Events

    • 26 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
    • 08 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top